On September 11, 2015, the National Heart, Lung, and Blood Institute (NHLBI) announced that it was stopping its Systolic Pressure Intervention Trial (“SPRINT”). The Institute’s Data Safety and Monitoring Board (DSMB) had reviewed interim data and concluded that the results demonstrated clear benefit from aggressive blood pressure lowering. The trial enrolled over 9300 adults with systolic hypertension and increased cardiovascular risk and randomized them to standard control (aiming for a target systolic blood pressure of 140 mm Hg) or to aggressive control (aiming for a target blood pressure of 120 mm Hg). ….
December 18, 2015